Endocrinology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Diabetes Res Clin Pract. 2011 Jul;93(1):e25-8. doi: 10.1016/j.diabres.2011.03.009. Epub 2011 Mar 26.
A randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status.
一项随机、交叉研究比较了阿托伐他汀、吉非贝齐及其联合应用对 2 型糖尿病患者炎症标志物的影响。测定了 C 反应蛋白（CRP）、脂蛋白相关磷脂酶 A2（Lp-PLA2）、分泌型磷脂酶 A2（sPLA2）、白细胞介素 8（IL8）、单核细胞趋化蛋白 1（MCP1）和肿瘤坏死因子α（TNFα）。两种降脂药物对炎症标志物均有积极的、互补的和累加的作用，与基线炎症状态密切相关。
